All In Biotech

Drug Trial Radar · NCT03293069

Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis

Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone

Last checked: Nov 20, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 372 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

372

Actual

Start

Jan 30, 2019

Primary completion

Nov 11, 2023

Study completion May 6, 2024

Sponsor

Lead sponsor
University Hospital, LilleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, France
First posted
Sep 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The alteration of iron metabolism is reported in animal models of amyotrophic lateral sclerosis (ALS) as well as in sporadic and genetic forms (SOD1 and C9orf72) of ALS. The high iron concentration of the brain, due to its high energy demand (high oxygen consumption), makes motor neurons particularly vulnerable to energy deficit and oxidative stress. Post-mortem examinations and MRI scans in patients with ALS have found signs of iron accumulation in the central motor tract; and a high level of serum ferritin, which is a marker of iron levels, is associated with a lower prognosis. In ALS mouse models, the use of iron chelators has demonstrated neuroprotection and increased life expectancy, suggesting that elimination of excess iron from the brain can prevent neuronal loss and, consequently, a slow progression of the disease. Conservative chelation of iron refers to a modality whereby much of the iron that binds to the chelator is redistributed in the body rather than exhausted. Using a chelator, deferiprone, with this feature, in a safety pilot study, a very good safety profile was observed. Deferiprone eliminated excess iron from brain regions, reduced oxidative damage and cell death associated with regional iron deposits with no apparent negative impact on the iron levels needed. Now, the efficacy of this new therapeutic modality of neuroprotection is being evaluated in a randomized, double-blind, placebo-controlled, multicenter study.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • DeferiproneDrug

    One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day

  • Placebo Oral TabletDrug

    the placebo twice daily morning and evening.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CAFS score (Combined Assessment of Function and Survival)Time frame: at 12 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Chr Angers

    Angers, France

  • Chru Brest

    Brest, France

  • Hopital Pierre Wertheimer - Hcl - Bron

    Bron, France

  • Chu Cote de Nacre - Caen

    Caen, France

  • Chu de Clermont-Ferrand

    Clermont-Ferrand, France

  • Hôpital Roger Salengro, CHU

    Lille, France

  • C H U Dupuytren Limoges

    Limoges, France

  • Aphm Hopital La Timone

    Marseille, France

  • Chu de Nancy

    Nancy, France

  • Chu de Nice Hopital Pasteur

    Nice, France

  • Hu Pitie Salpetriere Aphp

    Paris, France

  • Hopital de Hautepierre

    Strasbourg, France

  • Chu de Bordeaux - Talence

    Talence, France

  • Chu Toulouse

    Toulouse, France

  • Chu de Tours

    Tours, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.